TOP TEN perturbations for 39382_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39382_at
Selected probe(set): 202341_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39382_at (202341_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):4.4367647Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
HCC827 / A-549
Relative Expression (log2-ratio):4.1812086Number of Samples:6 / 6
| Experimental | HCC827 |
| Human primary cancer cell line derived from the lung of a patient with non-small-cell lung cancer. Synonyms:HCC-827; HCC0827 Cellosaurus code: | |
| Control | A-549 |
| Human primary cancer cell line derived from the lung of a patient with carcinoma. Synonyms:A 549; A549; NCI-A549; A549/ATCC; hA549 Cellosaurus code: |
hair follicle keratinocyte study 1 (CD200-/CD49+) / hair follicle keratinocyte study 1 (CD200+/CD49+)
Relative Expression (log2-ratio):-4.1310644Number of Samples:3 / 3
| Experimental | hair follicle keratinocyte study 1 (CD200-/CD49+) |
| Primary hair follicle keratinocytes sample negative for CD200 and positive for CD49. | |
| Control | hair follicle keratinocyte study 1 (CD200+/CD49+) |
| Primary hair follicle keratinocytes sample positive for CD200 and CD49. |
expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):-3.9232197Number of Samples:3 / 4
| Experimental | expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid. | |
| Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
expO kidney cancer study 1 (neoplasm, malignant; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):-3.4777393Number of Samples:2 / 4
| Experimental | expO kidney cancer study 1 (neoplasm, malignant; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm. | |
| Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)
Relative Expression (log2-ratio):-3.4707403Number of Samples:4 / 3
| Experimental | lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). |
tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):3.4343767Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
scleroderma study 8 (skin; anifrolumab; 5mg/kg;/wk; multiple dose; 28d) / scleroderma study 8 (skin; baseline; 5mg/kg/wk; multiple dose)
Relative Expression (log2-ratio):-3.4251661Number of Samples:2 / 4
| Experimental | scleroderma study 8 (skin; anifrolumab; 5mg/kg;/wk; multiple dose; 28d) |
| Skin tissue samples collected from adult systemic sclerosis patients at day 28 after a 4-week repeated intravenous injection of anifrolumab (5 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). ATC code:--- | |
| Control | scleroderma study 8 (skin; baseline; 5mg/kg/wk; multiple dose) |
| Skin tissue samples from adult systemic sclerosis patients before a 4-week repeated intravenous injection of anifrolumab (5 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). |
scleroderma study 8 (skin; anifrolumab; 5mg/kg;/wk; multiple dose; 28d) / scleroderma study 8 (skin; anifrolumab; 1mg/kg/wk; multiple dose; 28d)
Relative Expression (log2-ratio):-3.403016Number of Samples:2 / 4
| Experimental | scleroderma study 8 (skin; anifrolumab; 5mg/kg;/wk; multiple dose; 28d) |
| Skin tissue samples collected from adult systemic sclerosis patients at day 28 after a 4-week repeated intravenous injection of anifrolumab (5 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). ATC code:--- | |
| Control | scleroderma study 8 (skin; anifrolumab; 1mg/kg/wk; multiple dose; 28d) |
| Skin tissue samples collected from adult systemic sclerosis patients at day 28 after a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1. ATC code:--- |
expO kidney cancer study 1 (granular cell carcinoma; primary) / expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):3.3535776Number of Samples:4 / 207
| Experimental | expO kidney cancer study 1 (granular cell carcinoma; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. | |
| Control | expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with clear cell adenocarcinoma (NOS). |